Previous 10 | Next 10 |
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data ...
Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...
BioCardia (BCDA) inks agreements for the purchase and sale of 2,038,836 common shares at a purchase price of $5.15/share in a registered direct offering priced at-the-market. A.G.P./Alliance Global Partners is acting as sole placement agent.Closing date is December 18.Shares down 11% ...
SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 2,038,836 shares of its common stock at a purchase...
Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...
Gainers: Anchiano Therapeutics ANCN +173%, Prevail Therapeutics PRVL +84%, BioCardia (BCDA) +40%, Solid Biosciences (SLDB) +37%, OncoCyte OCX +32%.Losers: Mirum Pharmaceuticals (MIRM) -21%, Mesoblast (MESO) -18%, Rubius Therapeutics ...
Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...
SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase ...
BioCardia ([[BCDA]] +81.2%) announces direct offering of 1,888,889 shares of its common stock at a purchase price of $4.75/share.The offer is expected to close on Dec. 16, 2020.Previously: BioCardia says DSMB feedback on cell therapy data in heart failure study anticipated soon (Dec. 14)...
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase ...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therap...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...